checkAd

Delisting of Kiadis will be effective on 25 May 2021

Nachrichtenquelle: globenewswire
26.04.2021, 18:00  |  183   |   |   

This is a joint press release by Sanofi Foreign Participations B.V. (the “Offeror”), Sanofi (“Sanofi) and Kiadis Pharma N.V. (Kiadis) in connection with the recommended public offer by the Offeror for all the issued and outstanding ordinary shares in the capital of Kiadis (the Offer). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. Any offer will be made only by means of the offer memorandum dated 10 February 2021 (the Offer Memorandum”), approved by the Dutch Authority for the Financial Markets (Autoriteit Financiële Markten) on 10 February 2021 and recognized by the Belgian Authority for the Financial Markets (Autoriteit voor Financiële Diensten en Markten) on 11 February 2021. This announcement is not for release, publication or distribution, in whole or in part, in or into, directly or indirectly, any jurisdiction in which such release, publication or distribution would be unlawful. Terms not defined in this press release will have the meaning as set forth in the Offer Memorandum.

Delisting of Kiadis will be effective on 25 May 2021

  • Settlement of the Offer took place on 16 April 2021.
  • Sanofi will initiate statutory Buy-Out proceedings in an expeditious manner in order to obtain 100% of the Shares.
  • The last trading date of the Shares on Euronext Amsterdam and Euronext Brussels ("Euronext") will be on 24 May 2021 and listing and trading of the Shares will terminate as of 25 May 2021.

Paris, France and Amsterdam, The Netherlands, 26 April 2021 – The Offeror, Sanofi (Euronext: SAN and NYSE: SNY) and Kiadis (Euronext Amsterdam and Brussels: KDS) today announce that the listing and trading of the Shares on Euronext will be terminated. In consultation with Euronext, it has been decided that the last day of trading of the Shares will be on 24 May 2021. This means that the termination of the listing of the Shares shall be effective as of 25 May 2021. Reference is made to Sections 6.11(a) (Intentions following the Offer being declared unconditional) and Section 6.11(b) (Liquidity and delisting) of the Offer Memorandum.

Buy-Out
Since the Offeror owns more than 95% of the Shares, the Offeror will initiate the statutory Buy-Out in an expeditious manner in order to obtain 100% of the Shares. Reference is made to Section 6.11(c) (Buy-Out) of the Offer Memorandum.

Dutch Translation/Nederlandse vertaling

Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Delisting of Kiadis will be effective on 25 May 2021 This is a joint press release by Sanofi Foreign Participations B.V. (the “Offeror”), Sanofi (“Sanofi”) and Kiadis Pharma N.V. (“Kiadis”) in connection with the recommended public offer by the Offeror for all the issued and outstanding ordinary …

Community

Nachrichten des Autors

Titel
Titel
Titel
Titel